KB-1041

10A7-mIgG2a

12073

Home » 10A7-mIgG2a

Background of 10A7-mIgG2a

TIGIT is an inhibitory receptor expressed on lymphocytes that was recently propelled under the spotlight as a major emerging target in cancer immunotherapy. TIGIT interacts with CD155 expressed on antigen-presenting cells or tumour cells to downregulate T cell and natural killer (NK) cell functions. TIGIT has emerged as a key inhibitor of anti-tumour responses that can hinder multiple steps of the cancer immunity cycle. Pre-clinical studies indicated that TIGIT blockade may protect against various solid and haematological cancers.

Specifications

Catalog Number	KB-1041
Antibody Name	10A7-mIgG2a
Isotype	Mouse IgG2a,kappa
FC Muations	Wild Type
Target	Mouse-TIGIT
Species Reactivity	Mouse
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Manieri N A, Chiang E Y, Grogan J L. TIGIT: a key inhibitor of the cancer immunity cycle[J]. Trends in immunology, 2017, 38(1): 20-28.
He W , Zhang H , Han F , et al CD155T/TIGIT Signaling Regulates CD8+ T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer. Cancer Res 2017;77:6375–88.doi:10.1158/0008-5472.CAN-17-0381Y
Stanietsky N, Rovis TL, Glasner A, et al. Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. Eur J Immunol. 2013;43:2138–2150.